Sign in
Taking people in United KingdomNo phase

Ubiquinol for tiredness and muscle strength in adults taking GLP-1 weight loss medicines

Tests ubiquinol against placebo for fatigue and muscle strength in adults using GLP-1 medicines.

Key facts

Who runs it
StudySetGo
Where
Glasgow, United KingdomSee the site
Trial code
Registry title
A Study on Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Taking GLP-1 Agonists
Status
Recruiting
People taking part
90 people, planned
Started
1 Sept 2026
Expected to end
1 Sept 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Ubiquinol 100 MG Oral Capsule
  • Placebo
Record updated
19 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 30-65 who recently started Wegovy or Mounjaro for weight loss. It tests whether ubiquinol lowers fatigue and helps keep muscle strength.

Age
30 to 65 years
Sex
All sexes can join.
Disease stage
Body mass index above 27 and below 35 kg/m2. Must be able to do at least one sit-to-stand movement.
Earlier treatment
Must be starting, or have started within the last 16 weeks, semaglutide 2.4mg (Wegovy®) or tirzepatide (Mounjaro®) for weight management. Must not have used ubiquinol or Co-enzyme Q10 in the last 3 months, any statin, or other GLP-1 agonists before, or had bariatric surgery.
Biomarker or test result
Screening blood results must be within the lab reference range.

Main reasons for not taking part

  • Another condition that may affect fatigue, such as diabetes, heart disease, sleep apnoea, autoimmune disease, advanced liver disease or cancer
  • Current or past use of statin medication
  • Earlier use of GLP-1 agonists or bariatric surgery
  • Plan to stop the GLP-1 medicine within 9 months
  • Pregnancy, breastfeeding or plan to conceive during the study

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Age 30-65 years
  • Body mass index >27kg/m2 and <35 kg/m2
  • Currently initiating, or has initiated within the preceding 16 weeks of screening, one of the following MHRA-licensed weight management pharmacotherapies: semaglutide 2.4mg (Wegovy®) or tirzepatide (Mounjaro®) prescribed for the indication of weight management
  • Is physically mobile and able to complete at least one sit to stand movements
  • Owns a smartphone (iOS 15.6 or later, Android 9 or later) and is willing and able to install the SANNO Health app
  • Proficient in English language speaking and reading
  • Owns their own digital body weighing scale
  • Able and willing to provide full informed consent

Who cannot take part

  • Prior use of ubiquinol or Co-enzyme Q10 within 3 months of screening
  • Prior or current use of statin medication
  • Has previously used GLP-1 agonists and/or undergone bariatric surgery
  • Other medications, which in the opinion of the Chief Investigator, may deplete CoQ10
  • Diagnosed condition which, in the opinion of the Chief investigator, may independently impact fatigue (e.g. type 1 or type 2 diabetes, cardiovascular disease, obstructive sleep apnoea, inflammatory or autoimmune conditions, cirrhotic or advanced liver disease, malignancy)
  • Failed screening bloods (any results that is outside of the lab reference range)
  • Intention to stop GLP-1 agonist use within 9 months of randomisation
  • Pregnancy, breastfeeding or intention to conceive during study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 30 and 65 years old?

Where in United Kingdom

  • Office 1110 3 Fitzroy Place, 1/1, Sauchiehall StreetGlasgow, United KingdomContact: Tom JamesonTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if a daily ubiquinol supplement can reduce fatigue and help maintain muscle strength in adults aged 30-65 who are taking a GLP-1 weight loss medication (Wegovy® or Mounjaro®). Ubiquinol is a form of Coenzyme Q10 (CoQ10), a substance the body makes naturally that plays a key role in energy production. The main questions it aims to answer are:

Read full original descriptionShow less

Does ubiquinol lower fatigue levels compared to a placebo (a look-alike capsule that contains no ubiquinol)? Does ubiquinol help maintain muscle strength during weight loss treatment?

Researchers will compare ubiquinol to a placebo to see if ubiquinol helps with fatigue and muscle strength in people using GLP-1 medications.

Participants will:

Take one ubiquinol (100 mg) or placebo capsule every day for 9 months Have a nurse visit their home 4 times (at months 0, 3, 6, and 9) to take a small blood sample, measure their body, and supervise a simple sit-to-stand exercise test. Attend a short monthly video call (about 20-30 minutes) with a study dietitian. Complete questionnaires and 4 days of diet logging every 3 months using a smartphone app. Log all exercise sessions in the smartphone app throughout the study.

This is a fully remote study - participants do not need to visit a clinic. About 90 people will take part.

The 2 groups in the trial

  • UbiquinolTreatment being tested

    Treatment: Ubiquinol 100 MG Oral Capsule

  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomised, Placebo-Controlled Trial to Evaluate the Effect of Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Who Are Self-Administering GLP-1 Agonists ("Project Zest")
Plain-language title
Ubiquinol for tiredness and muscle strength in adults taking GLP-1 weight loss medicinesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Fit questions
Built from NCT07789106, who can take part
Record updated
19 October 2026